President Bill Clinton plans significant changes for this year’s Clinton Global Initiative annual meeting to address global ...

Gilead has returned the rights to a cancer candidate it licensed from Arcus Biosciences in a $725 million, multiprogram deal, ...

Gilead Sciences’ (NASDAQ: GILD) Q2 earnings are scheduled to be released on August 7, after market close. The pharma company ...